TheraRadar
← Back
Data updated: Jun 28, 2026

PATHEON SOFTGELS

Generics

PATHEON SOFTGELS is a generic drug manufacturer focused on Immunology.

2023
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

PATHEON SOFTGELS's Key Drugs

PATHEON SOFTGELS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PATHEON SOFTGELS's Recent FDA Approvals

New NDA/BLA approvals for PATHEON SOFTGELS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PATHEON SOFTGELS's Therapeutic Areas

PATHEON SOFTGELS's approved drugs and pipeline span 1 therapeutic area, led by Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 100%
1 drugs

PATHEON SOFTGELS's Top Competitors

PATHEON SOFTGELS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

PATHEON SOFTGELS Pipeline Snapshot

Active clinical trials for PATHEON SOFTGELS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling